Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. 2005N-0331]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of ten abbreviated new drug applications (ANDAs) held by Able Laboratories, Inc. (Able Labs), One Able Dr., Cranbury, NJ 08512. Able Labs has initiated a class II recall of the products covered by these ANDAs. The company has requested that the applications be withdrawn and has waived its opportunity for a hearing.
 DATES: Effective August 29, 2005.
 FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.


SUPPLEMENTARY INFORMATION: On May 25, 2005, Able Labs notified the agency that, because of improper laboratory practices and noncompliance with standard operating procedures, Able Labs was initiating a voluntary, class II recall of the products covered by the ANDAs listed in the table of this document. The company voluntarily requested withdrawal of approval of the ANDAs under § 314.150(d) (21 CFR 314.150(d)), and waived its opportunity for a hearing, provided under § 314.150(a) and (b). The following ANDAs are affected by this action: ANDA No.
Drug40-395
Diphenoxylate Hydrochloride (HCl) and Atropine Sulfate Tablets USP, 2.5 milligrams (mg)/0.025 mg40-404
Methylphenidate HCl Tablets USP, 5 mg, 10 mg, and 20 mg40-407
Prochlorperazine Suppositories USP, 2.5 mg, 5 mg, and 25 mg40-452
Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/30 mg40-459
Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/60 mg71-780
Clorazepate Dipotassium Tablets USP, 3.75 mg71-781
Clorazepate Dipotassium Tablets USP, 7.5 mg71-782
Clorazepate Dipotassium Tablets USP, 15 mg( print page 51076)75-838
Propoxyphene Napsylate and Acetaminophen Tablets USP, 100 mg/650 mg76-032
Methylphenidate HCl Exended-Release Tablets USP, 20 mg
 Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.105(a)), approval of the ANDAs listed in the table of this document, and all amendments and supplements thereto, is withdrawn, effective August 29, 2005. Thereafter, distribution of the products in interstate commerce without approved applications is illegal and subject to regulatory action. Also, on the basis of the circumstances described in this document that led to the recall of the products and their subsequent removal from the market, the agency will remove the products from the agency's list of drug products with effective approvals, published under the title “Approved Drug Products With Therapeutic Equivalence Evaluations.” This document serves as notice of the removal of the products covered by the ANDAs listed in this document from the list of approved drug products. Distribution of these products in interstate commerce without approved applications is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the act (21 U.S.C. 355(a) and 331(d)). Dated: August 15, 2005. Steven Galson, Director, Center for Drug Evaluation and Research.


[FR Doc. 05-17151 Filed 8-26-05; 8:45 am] BILLING CODE 4160-01-S